.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Fish and Richardson
Cerilliant
Cipla
Argus Health
Mallinckrodt
Julphar
Cantor Fitzgerald
Boehringer Ingelheim
Farmers Insurance

Generated: September 21, 2017

DrugPatentWatch Database Preview

NATRECOR Drug Profile

« Back to Dashboard

Which patents cover Natrecor, and when can generic versions of Natrecor launch?

Natrecor is a drug marketed by Scios Llc and is included in one NDA.

The generic ingredient in NATRECOR is nesiritide recombinant. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nesiritide recombinant profile page.

Summary for Tradename: NATRECOR

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list33
Drug Prices:see details
DailyMed Link:NATRECOR at DailyMed

Pharmacology for Tradename: NATRECOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Scios Llc
NATRECOR
nesiritide recombinant
FOR SOLUTION;INTRAVENOUS020920-001Aug 10, 2001RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NATRECOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Scios Llc
NATRECOR
nesiritide recombinant
FOR SOLUTION;INTRAVENOUS020920-001Aug 10, 2001► Subscribe► Subscribe
Scios Llc
NATRECOR
nesiritide recombinant
FOR SOLUTION;INTRAVENOUS020920-001Aug 10, 2001► Subscribe► Subscribe
Scios Llc
NATRECOR
nesiritide recombinant
FOR SOLUTION;INTRAVENOUS020920-001Aug 10, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Chinese Patent Office
Boehringer Ingelheim
Argus Health
Johnson and Johnson
Daiichi Sankyo
Mallinckrodt
Teva
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot